切除性乙型肝炎病毒和丙型肝炎病毒相关肝细胞癌的抗病毒治疗利用及10年结局
这项国际多中心队列研究纳入1906例接受治愈性肝切除术的HBV或HCV相关肝细胞癌患者,评估抗病毒治疗利用情况与长期总生存。抗病毒治疗与更长的长期生存相关,但利用率严重不足。
要点
- HBV相关HCC抗病毒利用率57%,随时间下降,2015年后降至47%。
- HCV相关HCC抗病毒利用率35%,2015年后升至74%。
- 抗病毒治疗与HBV和HCV相关HCC切除术后长期生存独立相关。
核心结论
- 抗病毒治疗与接受治愈性切除术的HBV或HCV相关HCC患者的长期生存相关,但抗病毒治疗严重利用不足。
研究设计与样本
- 这项队列研究纳入来自12个国际中心的1906例参与者,其中HBV相关HCC 1054例,HCV相关HCC 852例,所有参与者均患有HBV或HCV相关HCC并接受了治愈性手术切除。
主要发现
- 平均(±标准差)年龄为62.1(±11.3)岁,74%为男性,84%为亚洲人。
- 在整个队列平均(±标准差)5.0(±4.3)年的随访期间,47%的参与者接受了抗病毒治疗。
- HBV相关HCC参与者的总体抗病毒利用率为57%,并随时间下降:2010年前为65%,2010年至2015年为60%,2015年后为47%,P < .0001。
- HCV相关HCC参与者的总体抗病毒利用率为35%,并随时间上升:2015年前为24%,2015年及以后为74%,P < .0001。
- 10年OS在未治疗参与者中较低:HBV相关HCC未治疗者58% vs 治疗者61%,HCV相关HCC未治疗者38% vs 治疗者82%,两项P均 < .0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS: This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS: The mean (±standard deviation [SD]) age was 62.1 (±11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (±SD) follow-up of 5.0 (±4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION: Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized.
引用
- Huang DQ, Hoang JK, Kamal R, et al. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma. J Clin Oncol. 2024. PMID: 38175991. doi:10.1200/JCO.23.00757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。